Clinical trials
Lung Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting lung cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,796 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07114861RecruitingPhase 1/Phase 2
KN510713 with mFOLFIRINOX for advanced pancreatic cancer
This study tests a new drug (KN510713) combined with the standard chemotherapy mFOLFIRINOX for people with advanced pancreatic cancer that hasn't had prior chemotherapy. The goal is to see if adding the new drug can improve outcomes.
Goyang-siAges 19–75 - NCT05970497RecruitingPhase 1/Phase 2
KB707 trial for advanced solid tumors after other treatments
This early-stage trial tests KB707 in people with locally advanced or metastatic solid tumors that have not responded well to standard treatments. If you qualify, you may receive KB707 to see how well it can shrink tumors or control the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT07050043RecruitingPhase 3
Low-dose nivolumab plus chemo vs standard chemo for advanced lung cancer
This trial tests whether a lower dose of the immunotherapy drug nivolumab combined with standard chemotherapy works better than chemotherapy alone for people with advanced or metastatic non-small cell lung cancer (NSCLC) that has not been treated before.
Alor Star, KedahAges 18 years+ - NCT07054307RecruitingPhase 1
Study of MRG003 plus HX008 for EGFR-positive penile cancer
This trial tests two drugs, MRG003 and HX008, as a first treatment for men with EGFR-positive penile squamous cell carcinoma that cannot be removed by surgery or has spread. The goal is to see if the combination shrinks tumors or delays growth.
Chengdu, SichuanAges 18 years+ - NCT06926868RecruitingPhase 2/Phase 3
Study of a new drug versus chemotherapy for advanced triple-negative breast cancer
This trial tests a new investigational drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. The goal is to see if the new drug works better at shrinking or slowing the cancer.
Hot Springs, ArkansasAges 18 years+ - NCT06846996Recruiting
Study of trastuzumab deruxtecan for advanced stomach cancer
This study looks at how well the drug trastuzumab deruxtecan (T-DXd) works and how safe it is in people with advanced HER2-positive stomach or gastroesophageal junction cancer in China. It may be an option if you have already had other treatments.
BeijingAges 18 years+ - NCT06833229Recruiting
Can a PET scan predict if immunotherapy is working?
This study uses a special PET-CT scan early in your treatment to see if immunotherapy (with or without chemotherapy) is working against your advanced lung cancer. The goal is to find out faster if the treatment is helping.
NiceAges 18 years+ - NCT06805825RecruitingPhase 1
Study of NN3201 for advanced cancers with c-Kit
This trial tests a new drug, NN3201, that targets a protein called c-Kit found on some cancer cells. It may be an option for people with certain advanced solid tumors, including GIST, small cell lung cancer, or other c-Kit-positive cancers, who have already tried standard treatments or cannot take them.
Ann Arbor, MichiganAges 18 years+ - NCT06745908RecruitingPhase 3
New drug combo for lung cancer after immunotherapy stops working
This trial tests a new drug combination (N-803 and tislelizumab with chemotherapy) for people whose lung cancer stopped responding to standard immunotherapy. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
Springdale, ArkansasAges 18–90 - NCT06667960RecruitingPhase 1/Phase 2
Study of JK06 for advanced solid tumors
This trial tests a new drug called JK06 for people with advanced solid tumors that cannot be removed by surgery or have spread. It aims to see if JK06 is safe and effective.
AntwerpAges 18 years+ - NCT06600906Recruiting
MRI test to predict treatment response in pancreatic cancer
This study is testing a new MRI technique that may help predict how well pancreatic cancer treatments will work. You would receive a special substance (called hyperpolarized pyruvate) during a standard MRI scan.
San Francisco, CaliforniaAges 18 years+ - NCT06359847RecruitingPhase 2
ST-1898 for advanced thyroid cancer that no longer responds to iodine therapy
This trial tests an experimental drug called ST-1898 for people with advanced thyroid cancer that has stopped responding to radioactive iodine treatment and has progressed after at least one targeted therapy. It aims to see if ST-1898 can shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06545747RecruitingPhase 3
MRI-guided radiation for advanced lung cancer
This trial tests a new way of giving radiation therapy for advanced lung cancer that cannot be surgically removed. It uses MRI scans to guide and adjust the radiation dose, which may help target the tumor more precisely and reduce side effects.
GuangzhouAges 18–75 - NCT06439771RecruitingPhase 2
Testing YL202 for advanced breast cancer
This trial tests a new drug called YL202 for people with advanced breast cancer. It is for those who have already tried certain targeted treatments (HER2 or TROP2 antibody-drug conjugates) and they stopped working. The goal is to see if YL202 can help shrink tumors or slow cancer growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06333314RecruitingPhase 2
Dostarlimab for advanced dMMR/MSI cancers (not colorectal or endometrial)
This trial tests a drug called dostarlimab for people with certain advanced cancers that have a specific genetic feature (dMMR/MSI-H). The goal is to see if it helps shrink or control the cancer in people who haven't had other treatments yet.
AngersAges 18 years+ - NCT06312176RecruitingPhase 3
Study of new drugs for HR+/HER2- advanced breast cancer
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
Chandler, ArizonaAges 18 years+ - NCT06266299RecruitingPhase 1
Study of KK2269 for adults with solid tumors
This trial tests a new drug called KK2269 for adults with solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective, possibly as a treatment option for certain cancers like lung or stomach cancer.
Scottsdale, ArizonaAges 18 years+ - NCT05733598RecruitingPhase 2
RP2 plus standard treatment for advanced liver or bile cancers
This Phase 2 trial studies whether RP2, added to standard second-line treatment, can improve outcomes for people with advanced liver cancer or bile duct/gallbladder cancer. It may help by training the immune system to better attack the cancer after the cancer has already grown despite prior treatment.
Beverly Hills, CaliforniaAges 18 years+ - NCT05702229RecruitingPhase 2
Study of combined medicines for advanced stomach cancer with Claudin18.2
This Phase 2 study tests new combination treatments for advanced stomach or stomach-esophagus junction cancer that cannot be removed by surgery. It may help people whose tumors are positive for a marker called Claudin18.2, which the study uses to choose who can receive the treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT05498792RecruitingEarly Phase 1
Trial testing CBL0137 with two immunotherapy drugs for melanoma
This early trial tests CBL0137 along with ipilimumab and nivolumab (two immune-based cancer medicines) in people with stage III or possibly stage IV melanoma that can be biopsied. It may help shrink melanoma and improve immune control, while also learning how safe and effective this combination is.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05257993RecruitingPhase 1/Phase 2
Pancreatic cancer trial testing JPI-547 with standard chemo
This study tests whether adding JPI-547 to standard chemotherapy (modified FOLFIRINOX or gemcitabine with nab-paclitaxel) is safe and tolerable in people with advanced pancreatic cancer. If it works, it may improve treatment options for cancers that have spread or cannot be removed with surgery.
Gyeonggi-doAges 19–79 - NCT05276726RecruitingPhase 1/Phase 2
Test drug JAB-21822 for KRAS G12C NSCLC with STK11
This trial studies how well the drug JAB-21822 works in people with advanced or spread lung cancer (NSCLC) that has a specific genetic change: KRAS G12C, plus STK11 and no KEAP1 change. It’s designed to see safety and early signs of effectiveness, especially if you haven’t been treated much yet.
Beijing, Beijing MunicipalityAges 18 years+ - NCT03521830RecruitingPhase 2
Nivolumab and other immunotherapy for advanced basal cell skin cancer
This study tests how well the immunotherapy medicine nivolumab works—either by itself or combined with other immune-boosting drugs—for people with advanced basal cell carcinoma that can’t be removed by surgery or has spread. It’s also looking at what to do if the cancer grows again after an earlier immunotherapy.
Baltimore, MarylandAges 18 years+ - NCT05735080RecruitingPhase 1/Phase 2
INX-315 for advanced cancers with a specific gene change
This trial studies an experimental medicine (INX-315) given in an “open-label” way to people with advanced cancer that has not responded to prior treatment. It mainly looks at safety and side effects first, and also checks how well it works in cancers with a specific gene amplification.
Orlando, FloridaAges 18 years+
Hear when a new Lung Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,796 recruiting lung cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.